DNA Synthesis

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the DNA synthesis technologies and services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to DNA synthesis technologies. The chapter features a detailed discussion on the components of DNA synthesis, leading and lagging strand synthesis and the chemical and enzymatic method of DNA synthesis. In addition, it discusses the various applications and future prospects of display technologies.

Chapter 4 provides a detailed assessment of the overall landscape of the DNA synthesis technologies and services market, providing information on type of offering, method of DNA synthesis (chemical method and enzymatic method), type of DNA molecule, custom offerings, and application area. Additionally, the report provides information on drug developer(s) involved in the domain, along with analyses based on a number of relevant parameters, such as year of establishment, company size and geographical location of headquarters.

Chapter 5 features elaborate profiles of the key players involved in providing technologies and services for DNA synthesis. Each profile features a brief overview of the company, its financial information, details on its technology / service portfolio, financial information and recent developments and an informed future outlook.

Chapter 6 is a case study featuring a detailed overview of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

Chapter 7  is a case study featuring  a detailed overview of the current market landscape of oligonucleotide manufacturers focused on therapeutic applications, based on several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with information on the location of facility (country-wise), regulatory accreditations and certifications received, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, fill / finish, regulatory support, data analytics and reporting, and others) and type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications and others).

Chapter 8 features an analysis of the partnerships established between various stakeholders in this domain, during the period 2017-2022, covering product development and commercialization agreements, R&D agreements, technology licensing agreements, other licensing agreements, mergers and acquisitions, and other relevant types of deals.

Chapter 9 features a review of the funding and investments made in the domain, in the period between 2017 and 2022, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development. The analysis has been done on the basis of several parameters, such year of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 10 provides an in-depth analysis of academic grants that have been awarded to various research institutes for projects related to DNA synthesis technologies and services, during the period, 2017- 2022, on the basis of important parameters, such as year of grant award, amount awarded, type of funding institute, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization, study section and type of grant application. The chapter also highlights the popular recipient organizations (in terms of number of grants and amount awarded) and prominent program officers.

Chapter 11 provides a detailed review of more than 12,000 peer-reviewed, scientific articles related to research on DNA synthesis technologies, which have been published between 2017 and 2022, including analysis based on parameters, such as year of publication, key focus area, type of article, popular keywords, popular authors, therapeutic area, geography and key journals (in terms of number of articles published in this domain and impact factor of the journal).

Chapter 12 provides an overview of the various patents that have been filed / granted, since 2017, based on various parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry players (in terms of number of patents filed). In addition, the chapter also features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 

Chapter 13 includes an insightful market forecast analysis, highlighting growth opportunities of DNA synthesis services market till the year 2035. In addition, we have provided inputs on the likely distribution of the market opportunity based on different method of DNA synthesis (chemical method and enzymatic method), application area (research & diagnostics, and therapeutics applications), company size (small, mid-sized and large) and key geographical regions (North America, Europe and Asia-Pacific and RoW). To account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the DNA synthesis services and technologies market.

Chapter 15 is a collection of interview transcript(s) of the discussions held with key stakeholders in this industry.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to DNA Synthesis
3.3. Components of DNA Synthesis
3.3.1. Substrates
3.3.2. Template
3.3.3. Primer
3.3.4. Enzymes
3.3.5. Leading Strand Synthesis
3.3.6. Lagging Strand Synthesis
3.4. DNA Synthesis Technologies
3.4.1. Chemical Method of DNA Synthesis
3.4.2. Enzymatic Method of DNA Synthesis
3.5. Applications of DNA Synthesis
3.6. Future Perspectives

4. MARKET OVERVIEW: DNA SYNTHESIS TECHNOLOGIES AND SERVICES
4.1. Chapter Overview
4.2. DNA Synthesis Technologies and Services: Overall Market Landscape
4.2.1. Analysis by Type of Offering
4.2.2. Analysis by Method of DNA Synthesis
4.2.3. Analysis by Type of DNA Molecule
4.2.4. Analysis by Custom Offerings
4.2.5. Analysis by Application Area

4.3. DNA Synthesis Technologies and Services: Key Industry Players
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Application Area and Region

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Ajinomoto Bio-Pharma Services
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Technology / Service Portfolio
5.2.4. Recent Developments and Future Outlook

5.3. ATUM
5.3.1. Company overview
5.3.2. Technology / Service Portfolio
5.3.3. Recent Developments and Future Outlook

5.4. DNA Script
5.4.1. Company Overview
5.4.2. Technology / Service Portfolio
5.4.3. Recent Developments and Future Outlook

5.5. Eurofins Genomics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Technology / Service Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. Gene Universal
5.6.1. Company Overview
5.6.2. Technology / Service Portfolio
5.6.3. Recent Developments and Future Outlook

5.7. GenScript
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Technology / Service Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Synbio Technologies
5.8.1. Company overview
5.8.2. Technology / Service Portfolio
5.8.3. Recent Developments and Future Outlook

6. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
6.1. Chapter Overview
6.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Scale of Operation
6.2.4. Analysis by Geographical Location
6.2.5. Analysis by Location of Manufacturing Facilities
6.2.6. Analysis by Regulatory Accreditations / Certifications Received
6.2.7. Analysis by Type of Oligonucleotide Manufactured
6.2.8. Analysis by Type of Offering
6.2.9. Analysis by Type of Manufacturing Service Offered
6.2.10. Analysis by Type of Modification

7. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
7.1. Chapter Overview
7.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Scale of Operation
7.2.4. Analysis by Geographical Location
7.2.5. Analysis by Location of Manufacturing Facilities
7.2.6. Analysis by Regulatory Accreditations / Certifications
7.2.7. Analysis by Type of Oligonucleotide Manufactured
7.2.8. Analysis by Type of Offering
7.2.9. Analysis by Type of Manufacturing Service Offered
7.2.10. Analysis by Type of Modification

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Synthesis Technologies and Services: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Year and Type of Partner
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.6.1. Intercontinental and Intracontinental Agreements

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Synthesis Technologies: Recent Funding Instances
9.4. Analysis by Year of Investment
9.5. Analysis by Amount Invested
9.5. Analysis by Amount Invested

9.6. Analysis by Type of Funding and Amount Invested
9.7. Analysis by Venture Capital Funding
9.8. Most Active Players: Analysis by Number of Funding Instances
9.9. Key Investors: Analysis by Number of Funding Instances
9.10. Regional Analysis by Amount Invested
9.11. Funding and Investment Summary

10. GRANT ANALYSIS
10.1 Chapter Overview
10.2. Analysis Methodology and Key Parameters
10.3. DNA Synthesis Technologies and Services: List of Academic Grants
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Grant Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Administering Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Grant Activity Code
10.3.8. Word Cloud of Study Titles
10.3.9. Analysis by Purpose of Grant Award
10.3.10. Popular NIH Departments: Analysis by Number of Grants
10.3.11. Analysis by Type of Recipient Organization
10..12. Prominent Program Officers: Analysis by Number of Grants

11. PUBLICATION ANALYSIS
11.1. Chapter Overview
11.2. Analysis Methodology and Key Parameters
11.3. Analysis by Year of Publication
11.4. Analysis by Quarterly Distribution of Publication
11.5. Analysis by Type of Article
11.6. Analysis by Popular Keywords
11.7. Most Popular Authors: Analysis by Number of Publications
11.8. Popular Publishers: Analysis by Number of Publications
11.9. Popular Journals: Analysis by Number of Publications
11.10. Analysis by Therapeutic Area
11.11. Geographical Analysis

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Analysis Methodology and Key Parameters
12.3. DNA Synthesis Technologies and Services: Patent Analysis
12.3.1. Analysis by Type of Patent
12.3.2. Analysis by Publication Year
12.3.3. Analysis by Type of Patent and Publication Year
12.3.3. Analysis by Issuing Authority
12.3.4. Analysis by CPC Symbols
12.3.5. Analysis by Type of Applicant
12.3.6. Word Cloud Analysis: Emerging Focus Areas
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Players: Analysis by Number of Patents
12.3.10. Leading Patents: International Patents
12.3.11. Analysis by Patent Characteristics
12.3.12. Patent Valuation Analysis

13. DNA SYNTHESIS SERVICES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1 Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global DNA Synthesis Services Market, 2022-2035
13.3.1. Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035
13.3.2. Global DNA Synthesis Services Market: Distribution by Application Area, 2022-2035
13.3.3. Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035
13.3.4. Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035

13.4. DNA Synthesis Services Market in North America, 2022-2035
13.4.1. DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035
13.4.2. DNA Synthesis Services Market in North America: Distribution by Application Area, 2022-2035
13.4.3. DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035

13.5. DNA Synthesis Services Market in Europe, 2022-2035
13.5.1. DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035
13.5.2. DNA Synthesis Services Market in Europe: Distribution by Application Area, 2022-2035
13.5.3. DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035

13.6. DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022-2035
13.6.1. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035
13.6.2. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Application Area, 2022-2035
13.6.3. DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035

14. CONCLUDING REMARKS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 DNA Synthesis 5’ to 3’
Figure 3.2 DNA Synthesis: Direction of Fork Movement
Figure 3.3 Leading Strand Synthesis
Figure 3.4 Lagging Strand Synthesis
Figure 3.5 Applications of DNA Synthesis
Figure 4.1 DNA Synthesis Technologies and Services: Distribution by Type of Offering
Figure 4.2 DNA Synthesis Technologies and Services: Distribution by Method of DNA Synthesis
Figure 4.3 DNA Synthesis Technologies and Services: Distribution by Type of DNA Molecule
Figure 4.4 DNA Synthesis Technologies and Services: Distribution by Custom Offerings
Figure 4.5 DNA Synthesis Technologies and Services: Distribution by Application Area
Figure 4.6 DNA Synthesis Technologies and Service Providers: Distribution by Year of Establishment
Figure 4.7 DNA Synthesis Technologies and Service Providers: Distribution by Company Size
Figure 4.8 DNA Synthesis Technologies and Service Providers: Distribution by Location of Headquarters
Figure 4.9 DNA Synthesis Technologies and Service Providers: Distribution by Application Area and Region
Figure 5.1 Ajinomoto Bio-Pharma Services: Annual Revenues FY 2018- H1 2021 (JPY Billion)
Figure 5.2 Eurofins Genomics: Annual Revenues FY 2018- FY 2021 (JPY Billion)
Figure 5.3 GenScript: Annual Revenues, FY 2018- H1 2021 (USD Billion)
Figure 6.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 6.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 6.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 6.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Geographical Location
Figure 6.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 6.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 6.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 6.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Figure 6.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
Figure 6.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis)
Figure 6.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 7.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 7.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 7.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 7.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Geographical Location
Figure 7.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 7.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 7.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 7.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Figure 7.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering
Figure 7.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification)
Figure 7.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service (s) Offered
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Regional Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 DNA Synthesis Technologies: Cumulative Distribution by Year of Investment, 2017-2022
Figure 9.2 DNA Synthesis Technologies: Cumulative Amount Invested by Year, 2017- 2022 (USD Million)
Figure 9.3 Funding and Investments: Distribution by Type of Funding
Figure 9.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.5 Funding and Investments: Distribution by Type of Venture Capital Funding
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Most Active Players: Distribution by Amount Raised, 2017-2022 (USD Million)
Figure 9.8 Funding and Investments: Distribution of Investors by Number of Instances
Figure 9.9 Funding and Investments: Regional Distribution by Amount Invested, 2017-2022
Figure 9.10 Summary of Funding and Investments
Figure 10.1. Grant Analysis: Distribution by Year of Grant Award (FY 2017 – Q1 2022)
Figure 10.2. Grant Analysis: Distribution by Grant Amount Awarded (USD Million)
Figure 10.3. Grant Analysis: Distribution by Administering Institute Center
Figure 10.4. Grant Analysis: Distribution by Support Period
Figure 10.5. Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 10.6. Grant Analysis: Distribution by Type of Grant Application
Figure 10.7. Grant Analysis: Distribution by Grant Activity Code
Figure 10.8. Word Cloud Analysis: Emerging Focus Areas
Figure 10.9. Grant Analysis: Distribution by Purpose of Grant Award
Figure 10.10. Popular NIH Departments: Distribution by Number of Grants
Figure 10.11. Grant Analysis: Distribution by Type of Recipient Organization
Figure 10.12. Prominent Program Officers: Distribution by Number of Grants
Figure 11.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 11.2 Publication Analysis: Quarterly Distribution of Publications, 2017-2022
Figure 11.3 Publication Analysis: Distribution by Type of Article
Figure 11.4 Word Cloud Analysis: Emerging Focus Areas
Figure 11.5 Analysis by Popular Keywords
Figure 11.6 Most Popular Authors: Distribution by Number of Publications
Figure 11.7 Popular Publishers: Distribution by Number of Publications
Figure 11.8 Popular Journals: Distribution by Number of Publications
Figure 11.9 Publication Analysis: Distribution by Therapeutic Area
Figure 11.10 Publication Analysis: Distribution by Geography
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Distribution by Publication Year (Pre-2017, Q1 2022)
Figure 12.3 Patent Analysis: Year-wise Distribution of Granted Patents, Pre-2017, Q1 2022
Figure 12.4 Patent Analysis: Year-wise Distribution of Filed Patents, Pre-2017, Q1 2022
Figure 12.5 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 12.6 Patent Analysis: Distribution by Issuing Authority
Figure 12.7 Patent Analysis: Distribution by CPC Symbols
Figure 12.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 12.9 Word Cloud Analysis: Emerging Focus Areas
Figure 12.10 Leading Industry Players: Distribution by Number of Patents
Figure 12.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 12.12 Patent Analysis: Distribution by Patent Age
Figure 12.13 Patent Analysis: Distribution by Relative Valuation
Figure 13.1 Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.2 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
Figure 13.3 Global DNA Synthesis Services Market: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.4 Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035 (USD Million)
Figure 13.5 DNA Synthesis Services Market in North America, 2022-2035 (USD Million)
Figure 13.6 DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.7 DNA Synthesis Services Market in North America: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.8 DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035 (USD Million)
Figure 13.9 DNA Synthesis Services Market in Europe, 2022-2035 (USD Million)
Figure 13.10 DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.11 DNA Synthesis Services Market in Europe: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.12 DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035 (USD Million)
Figure 13.13 DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022- 2035 (USD Million)
Figure 13.14 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Figure 13.15 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Application Area, 2022-2035 (USD Million)
Figure 13.16 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035 (USD Million)
Figure 14.1 Concluding Remarks: Overall Market Landscape of DNA Synthesis Technologies and Services
Figure 14.2 Concluding Remarks: Partnerships and Collaborations
Figure 14.3 Concluding Remarks: Funding and Investments
Figure 14.4 Concluding Remarks: Grant Analysis
Figure 14.5 Concluding Remarks: Publication Analysis
Figure 14.6 Concluding Remarks: Patent Analysis

List Of Tables

Table 4.1 DNA Synthesis Technologies and Services: Information on Developers, Type of Offering, Method of DNA Synthesis, Type of DNA Molecule, Custom Offerings and Type of Application Area
Table 4.2 DNA Synthesis Technologies and Services Providers: Information on Year of Establishment, Company Size and Geography
Table 5.1 DNA Synthesis Technology and Service Providers: List of Companies Profiled
Table 5.2 Ajinomoto Bio-Pharma Services: Company Snapshot
Table 5.3 Ajinomoto Bio-Pharma Services: Technology / Service Portfolio
Table 5.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 5.5 ATUM: Company Snapshot
Table 5.6 ATUM: Technology / Service Portfolio
Table 5.7 DNA Script: Company Snapshot
Table 5.8 DNA Script: Technology / Service Portfolio
Table 5.9 DNA Script: Recent Developments and Future Outlook
Table 5.10 Eurofins Genomics: Company Snapshot
Table 5.11 Eurofins Genomics: Technology / Service Portfolio
Table 5.12 Gene Universal: Company Snapshot
Table 5.13 Gene Universal: Technology / Service Portfolio
Table 5.14 GenScript: Company Snapshot
Table 5.15 GenScript Technology / Service Portfolio
Table 5.16 GenScript: Recent Developments and Future Outlook
Table 5.17 Synbio Technologies: Company Snapshot
Table 5.18 Synbio Technologies: Technology / Service Portfolio
Table 6.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 6.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 6.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Service(s) Offered
Table 6.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
Table 6.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) and Type of Purification Method(s) Used
Table 7.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 7.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 7.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 7.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
Table 7.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) and Type of Purification Method(s) Used
Table 8.1 DNA Synthesis Technologies and Services Providers: List of Partnerships and Collaborations, 2017-2022 (till March)
Table 9.1 DNA Synthesis Technologies: List of Funding Instances, 2017-2022 (till March)
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 DNA Synthesis Technologies and Services: List of Academic Grants
Table 12.1 Patent Analysis: CPC Symbols
Table 12.2 Patent Analysis: Most Popular CPC Symbols
Table 12.3 Patent Analysis: List of Top 10 CPC Symbols
Table 12.4 Patent Analysis: List of Relatively High Value Patents
Table 16.1 DNA Synthesis Technologies and Services: Distribution by Type of Offering
Table 16.2 DNA Synthesis Technologies and Services: Distribution by Method of DNA Synthesis
Table 16.3 DNA Synthesis Technologies and Services: Distribution by Type of DNA Molecule
Table 16.4 DNA Synthesis Technologies and Services: Distribution by Custom Synthesis
Table 16.5 DNA Synthesis Technologies and Services: Distribution by Application Area
Table 16.6 DNA Synthesis Technologies and Service Providers: Distribution by Year of Establishment
Table 16.7 DNA Synthesis Technologies and Service Providers: Distribution by Company Size
Table 16.8 DNA Synthesis Technologies and Service Providers Distribution by Location of Headquarters
Table 16.9 DNA Synthesis Technologies and Service Providers Distribution by Application and Region
Table 16.10 Ajinomoto Bio-Pharma Services: Annual Revenues FY 2018- H1 2021 (JPY Billion)
Table 16.11 Eurofins Genomics: Annual Revenues FY 2018- H1 2021 (JPY Billion)
Table 16.12 GenScript: Annual Revenues, FY 2018- H1 2021 (USD Billion)
Table 16.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 16.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 16.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 16.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
Table 16.17 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 16.18 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Table 16.19 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 16.20 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Table 16.21 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering
Table 16.22 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis)
Table 16.23 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Table 16.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Table 16.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Table 16.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Table 16.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters6
Table 16.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 16.29 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Table 16.30 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Table 16.31 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Table 16.32 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering16
Table 16.33 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification)
Table 16.34 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service (s) Offered
Table 16.35 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Table 16.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.37 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Table 16.38 Most Active Players: Distribution by Number of Partnerships
Table 16.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.40 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 16.41 Partnerships and Collaborations: Regional Distribution
Table 16.42 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.43 DNA Synthesis Technologies: Distribution by Year of Investment, 2017-2022
Table 16.44 DNA Synthesis Technologies: Cumulative Amount Invested by Year, 2017-
2022 (USD Million) 
Table 16.45 Funding and Investments: Distribution by Type of Funding
Table 16.46 Funding and Investments: Distribution of Amount Invested by Type of
Funding (USD Million) 
Table 16.47 Distribution by Type of Venture Capital Funding
Table 16.48 Most Active Players: Distribution by Number of Funding Rounds
Table 16.49 Most Active Players: Distribution by Amount Raised 2017-2022 (USD
Million) 
Table 16.50 Funding and Investment: Distribution of investors by number of instances
Table 16.51 Funding and Investment Analysis: Regional Distribution of Total Amount
Invested, 2017-2022 
Table 16.52 Grant Analysis: Distribution by Year of Grant Award
Table 16.53 Grant Analysis: Distribution by Grant Amount Awarded
Table 16.54 Grant Analysis: Distribution by Administering Institute Center
Table 16.55 Grant Analysis: Distribution by Support Period
Table 16.56 Grant Analysis: Distribution by Administering Institute Center and Support
Year 
Table 16.57 Grant Analysis: Distribution by Type of Grant Application
Table 16.58 Grant Analysis: Distribution by Grant Activity Code
Table 16.59 Grant Analysis: Word Cloud of Study Titles
Table 16.60 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.61 Grant Analysis: Distribution by Type of Recipient Organization
Table 16.62 Popular NIH Departments: Distribution by Number of Grants
Table 16.63 Prominent Program Officers: Distribution by Number of Grants
Table 16.64 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Table 16.65 Publication Analysis: Quarterly Distribution of Publications
Table 16.66 Publication Analysis: Distribution by Type of Article
Table 16.67 Publication Analysis: Word Cloud of Study Titles
Table 16.68 Analysis by Popular Keywords
Table 16.69 Most Popular Authors: Distribution by Number of Publications
Table 16.70 Popular Publishers: Distribution by Number of Publications
Table 16.71 Popular Journals: Distribution by Number of Publications
Table 16.72 Popular Journals: Distribution by Number of Publications
Table 16.73 Publication Analysis: Distribution by Geography
Table 16.74 Patent Analysis: Distribution by Type of Patent
Table 16.75 Patent Analysis: Cumulative Distribution by Publication Year
Table 16.76 Patent Analysis: Distribution of Granted Patents by Publication Year
Table 16.77 Patent Analysis: Distribution of Filed Patents Publication Year
Table 16.78 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.79 Patent Analysis: Distribution by Issuing Authority
Table 16.80 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.81 Leading Industry Players: Distribution by Number of Patents
Table 16.82 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.83 Patent Analysis: Distribution by Patent Age
Table 16.84 Patent Analysis: Distribution by Relative Valuation
Table 16.85 Global DNA Synthesis Services Market: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.86 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.87 Global DNA Synthesis Services Market: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.88 Global DNA Synthesis Services Market: Distribution by Type of Application Area, 2022-2035 (USD Million)
Table 16.89 Global DNA Synthesis Services Market: Distribution by Geography, 2022-2035 (USD Million)
Table 16.90 DNA Synthesis Services Market in North America, 2022-2035 (USD Million)
Table 16.91 DNA Synthesis Services Market in North America: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.92 DNA Synthesis Services Market in North America: Distribution by Type of Application Area , 2022-2035 (USD Million)
Table 16.93 DNA Synthesis Services Market in North America: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.94 DNA Synthesis Services Market in Europe, 2022-2035 (USD Million)
Table 16.95 DNA Synthesis Services Market in Europe: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.96 DNA Synthesis Services Market in Europe: Distribution by Type of Application Area, 2022-2035 (USD Million)
Table 16.97 DNA Synthesis Services Market in Europe: Distribution by Company Size, 2022-2035 (USD Million)
Table 16.98 DNA Synthesis Services Market in Asia-Pacific and Rest of the World, 2022- 2035 (USD Million)
Table 16.99 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Method of DNA Synthesis, 2022-2035 (USD Million)
Table 16.100 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Application Area, 2022-2035 (USD Million)
Table 16.101 DNA Synthesis Services Market in Asia-Pacific and Rest of the World: Distribution by Company Size, 2022-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

1. Ajinomoto Bio-Pharma Services
2. Aldevron
3. AltaBioscience
4. Ansa Biotechnologies
5. Arbor Biosciences
6. ATUM
7. Beijing SBS
8. Bio Basic
9. Biolegio
10. Biomatik
11. Bioneer
12. Biosearch Technologies
13. Bio-Synthesis
14. Blue Heron Biotech
15. BOC Sciences
16. BR Biochem Life Sciences
17. Camena Bioscience
18. Catalog
19. ChemGenes Corporation
20. Creative Biogene
21. CustomArray
22. CyberGene
23. Dalton Pharma Services
24. DNA Script
25. Eton Bioscience (Subsidiary of Codex DNA)
26. Eurofins Genomics
27. Eurogentec
28. Evonetix
29. Futuresynthesis
30. Gene Universal
31. General Biosystems
32. Generi Biotech
33. Genewiz
34. GenScript
35. Glen Research
36. Helixworks Technologies
37. IBA Lifesciences
38. Integrated DNA Technologies
39. Iridia
40. KareBay Biochem
41. Kern Systems
42. Kilobaser
43. LC Sciences
44. metabion
45. Microsoft
46. Microsynth
47. Midland Certified Reagent Company
48. Molecular Assemblies
49. Moligo Technologies
50. Nitto Denko Avecia
51. Nuclera Nucleics
52. Oligomer Biotechnology
53. Origene
54. ProMab Biotechnologies
55. ProteoGenix
56. Quintaribio
57. Ribbon Biolabs
58. SARTOMED
59. Sigma-Aldrich (Acquired by Merck)
60. Sunomix Biosciences
61. Synbio Technologies
62. Syngene
63. SynHelix
64. Synthomics
65. TAG Copenhagen
66. Thermo Fisher Scientific
67. Xcelris Labs
68. Yale School of Medicine
69. GE Research
70. Baseclick
71. French Ministry for Armed Forces
72. Dynamic Combinatorial Chemistry (DCC)
73. Bright Peak Therapeutics
74. Trio Pharmaceuticals
75. GeneDesign
76. BIOfidal
77. Transcenta
78. Amptec 
79. Eton Bioscience
80. Glen Research Corporation
81. CodexisCodexis
82. TeselaGen Biotechnology
83. Analog Devices
84. imec
85. LioniX International
86. PeproTech
87. Patheon
88. GSL Biotech
89. Twist Bioscience
90. Horizon Discovery
91. CustomArray
92. Blue Heron Biotech
93. SynHelix
94. Isolere Bio
95. Aldevron
96. Biotechnolabs
97. iGEM
98. Integrated DNA Technologies
99. GENEWIZ
100. Eurofins Genomics
101. Kazusa DNA Research Institute
102. GeneBay
103. Aldevron
104. Agilent Technologies
105. Illumina Ventures
106. Sofinnova Partners
107. Kurma Partners
108. Casdin Capital
109. Danaher Life Sciences
110. M Ventures
111. Columbia Threadneedle Investments
112. Casdin Capital
113. Alexandria Venture Investments
114. iSelect Fund
115. Codexis
116. Argonautic Ventures
117. Horizons Ventures
118. Mubadala Capital
119. Humboldt Fund
120. National Science Foundation
121. Civilization Ventures
122. Illumina Ventures
123. Merck Ventures
124. Idinvest Partners
125. Bpifrance
126. Bpifrance
127. Life Sciences Partners
128. M. Ventures
129. Kurma Partners and Idinvest Partners
130. Bpifrance
131. Merck 
132. Life Sciences Partners
133. Bpifrance
134. Life Science Partners
135. Bpifrance Large Venture Fund
136. Alexandria Venture
137. Fidelity Management and Research
138. Arrowmark Partners
139. Farallon Capital
140. Moore Strategic Ventures
141. National Human Genome Research Institute
142. Coatue Management
143. Catalio Capital Management
144. Fidelity Management & Research Company
145. eureKARE
146. Irving Investors
147. IST Cube
148. tecnet equity
149. Hadean Ventures
150. Lansdowne Partners
151. Helicase Venture
152. IST cube
153. tecnet equity
154. iSelect Fund
155. Keshif Ventures
156. Agilent Technologies
157. LYFE Capital
158. National Human Genome Research Institute
159. SynBio Innovation Accelerator
160. LYFE Capital
161. DCVC
162. Rising Tide
163. Providence Investment Company Limited
164. Molten Ventures
165. Cambridge Consultants
166. Innovate UK
167. Draper Esprit
168. The Morningside Group
169. Providence Investment Company
170. Cambridge Consultants
171. Rising Tide Fund
172. Tech Coast Angels
173. The Department of Air Force
174. Department of Health and Human Services
175. TEEC Angel Fund
176. TA Associates
177. Colibri Ventures
178. Vanderbilt University
179. Division of Basic Sciences 
180. Columbia University Health Sciences
181. Medical College of Wisconsin
182. Eunice Kennedy Shriver National Institute of Child Health & Human Development
183. Univ Of North Carolina Chapel Hill
184. Weill Medical Coll of Cornell Univ
185. University of Minnesota
186. University of Iowa
187. National Institute on Aging
188. National Institute of Environmental Health Sciences
189. University of Wisconsin-Madison
190. Life Technologies
191. Tosoh
192. Achillion Pharmaceuticals
193. Harvard College
194. Broad Inst